Connect with us

Business

Most expensive home in South Surrey valued at $18016000 – Surrey Now-Leader

Published

 on


When Surrey and White Rock homeowners receive their assessment packages in the mail this week, BC Assessment says most will find a moderate change in the value of their property.

Examples provided by BC Assessment, designed to demonstrate market trends for single-family residential properties, show a four per cent increase in White Rock, from a typical assessed value of $1,195,000 last year to $1,245,000 this year, and a five per cent increase in Surrey, from $1,010,000 to $1,062,000.

The most expensive home in White Rock, which also ranked 483rd in the province in terms of value, is located at 13616 Marine Dr. Assessed at $10,475,000, the property experienced a slight decrease in value compared to last year, when it was assessed at $10,578,000. While the value of the land increased by $21,000, the buildings on the property decreased in value by $124,000.

The most expensive home in Surrey, located at 2021 Indian Fort Dr. and ranked 76th in the province, was assessed this year at $18,016,000, which is an increase from $17,948,000 last year.

In a Top 500 Valued Residential Properties list published last year, Surrey’s most expensive home, located at 17146 20 Ave., was assessed at $31.6 million.

However, BC Assessment deputy assessor Bryan Murao told Peace Arch News, the property was successful in achieving partial farm classification. The same property is now assessed at $8,174,520.

The only other Surrey home that placed on the top 500 list of most valued residential properties in the province is located at 2165 123 St., which is valued at $13,478,000 and ranked 228th.

SEE ALSO: Surrey, White Rock properties make list of most expensive in B.C.

In examples provided for strata homes, which includes townhouses and condos, White Rock was the only municipality in the Lower Mainland to experience a slight decrease in value. A typical assessed value of $460,000 in White Rock last year decreased to $452,000 this year, representing a two per cent downward shift.

In Surrey, however, a typical strata home assessment of $497,000 last year climbed to $510,000 this year, representing a three per cent change.

“Despite COVID-19, the Lower Mainland residential real estate market has been resilient,” said Murao. “For the most part, homeowners can expect relatively moderate increases in value. This incredible strength is a stark contrast to last spring when the market came to a temporary standstill, whereas the remainder of the year had a very steady and rapid recovery.”

However, Murao added, commercial and industrial markets have been much more varied with both decreases and increases, depending on the sector.

“While commercial sales activity has remained low, value changes have been moderate across many property types.”

The total number of properties in the province is 2,114,886, an approximate one per cent increase from 2020. In the Lower Mainland, the overall total assessments have increased from about $1.41 trillion in 2020 to about $1.46 trillion this year.

More than $15 billion of the Lower Mainland’s updated assessments comes from new construction, subdivisions and rezoning of properties.

Assessments are the estimate of a property’s market value as of July 1, 2020 and physical condition as of Oct. 31, 2020. Changes in property assessment reflect movement in the local real estate market and can vary greatly from property to property, BC Assessment said.

When estimating a property’s market value, BC Assessment analyzes current sales in the area as well as considering other characteristics such as size, age, quality, condition, view and location.



aaron.hinks@peacearchnews.com

Like us on Facebook and follow us on Twitter

HousingSurreyWhite Rock

Get local stories you won’t find anywhere else right to your inbox.
Sign up here

Let’s block ads! (Why?)



Source link

Continue Reading

Business

GameStop’s volatile rally smashes Wall St price targets – Aljazeera.com

Published

 on


The video game retailer’s stock surged as much as 145 percent to $159.18 on Monday, triggering at least nine trading halts.

To see how far GameStop Corp. has outrun anyone’s ability to render sensible analysis, consider what its current dizzying rally has done to Wall Street’s best guesses of its value.

Now perched close to $75 a share, hoisted by a short squeeze ignited and arguably organized in chat rooms, the game retailer’s stock is about $60 above the average forecast of equity handicappers tracked by Bloomberg. The ratio between the two is by far the biggest in the Russell 3000 and jumped for a third day, as crazed trading capped a stretch in which the 37-year-old company burned bears who had shorted 139% of its shares.

It’s happening in a stock that before 2020 had fallen six straight years as earnings shrunk, and which isn’t projected to turn a profit before fiscal 2023. While fundamentals may one day matter again, GameStop has now become the latest show of force by newbie day traders in a market that seems more like their plaything each day.

The stock surged as much as 145% to $159.18 on Monday, at one point triggering at least nine trading halts. It briefly turned negative before bouncing back to trade up 22% to $79.56 at 2 p.m. in New York. The shares have advanced more than 320% since the start of the year.

“It doesn’t make business sense,” said Doug Clinton, co-founder of Loup Ventures. “It makes sense from an investor psychology standpoint. I think there’s a tendency where there is heavy retail interest for those types of traders to think about stocks differently than institutional investors in terms of what they’re willing to pay.”

Right now, they’re willing to pay 471% more than what analysts consider reasonable, on average. While perhaps fairly priced relative to its annual sales of about $5.2 billion in the 12 months through October, those sales are down 40% in just two years. The company is expected to report a per-share loss in both fiscal 2021 and 2022. To get a price-earnings multiple it’s necessary to look two years into the future, where the P/E is around 58.

Bears have seen more than $6.1 billion mark-to-market losses this year, according to financial analytics firm S3 Partners.

While Wall Street may have no clue what GameStop shares are worth, it does have ideas on what the company should do with them: sell.

“GameStop can issue equity and should sell stock to pay down debt,” said Wedbush Securities Inc. analyst Michael Pachter, who had a price target of $16 for GameStop as of Jan. 11. Doing so would involve “minimal dilution at these levels” and provide protection against an economic downturn. “They should do as much as the market will absorb,” he said.

Separately, Telsey Advisory Group analyst Joseph Feldman double-downgraded the stock to underperform from outperform on Monday, removing GameStop’s only buy-or-equivalent recommendation.

Bullish Options

Whatever the future holds, the recent past has been a bonanza for anyone who dared own the stock — or, even better, bullish options. Calls expiring Jan. 29 with a strike price of $115 were the most-traded GameStop contract early Monday. Other similar wagers had correspondingly heady gains as contracts once seen as long-shot upward bets suddenly were in the money.

At investment research firm Hedgeye, analysts advised clients to not go short the stock, despite removing it from their “best idea long list” to reanalyze fundamentals. “Wouldn’t dare do that given the positive catalysts we think will be coming down the pike as the year progresses” with a very bullish calendar on the horizon, Brian McGough and Jeremy McLean wrote.

GameStop “has become a cult stock because of Ryan Cohen’s success with Chewy,” Wedbush’s Pachter said, referring to the activist investor and co-founder of online pet retailer Chewy Inc., who joined GameStop’s board this month. “I cannot discount Mr. Cohen’s past successes and don’t know what he has in mind going forward, but I need to see their strategy before I give them credit for materially higher earnings power.”

Let’s block ads! (Why?)



Source link

Continue Reading

Business

Canadian provinces push back vaccination plans as Pfizer deliveries grind to a halt – Canada News – Castanet.net

Published

 on


Some Canadian health-care workers are being told they’ll have to wait longer to receive their first doses of COVID-19 vaccines as deliveries from a major manufacturer grind to a temporary halt.

Canada is not expected to receive any Pfizer-BioNTech vaccines this week as the company revamps its operations, and deliveries are expected to be slow for the next few weeks.

Ontario announced today that it was pausing COVID-19 vaccinations of long-term care staff and essential caregivers so that it can focus on giving the shots to all nursing home residents.

Several provinces have used up nearly all their vaccine supply and have been forced to push back their vaccination schedules.

Saskatchewan announced Sunday that it had exhausted all the doses it has received so far, while Quebec has used up more than 90 per cent of its supply.

Prime Minister Justin Trudeau has said the delay is only temporary and that Canada is expected to receive 4 million doses of the Pfizer vaccine by the end of March.

Let’s block ads! (Why?)



Source link

Continue Reading

Business

Merck Gives Up on Coronavirus Vaccines – The Motley Fool

Published

 on


Pharmaceutical giant Merck (NYSE:MRK) officially threw in the towel on its efforts to develop a COVID-19 vaccine. The company said it’s discontinuing the development of two candidates, V590 and V591, after a review of results from phase 1 studies indicated that they were unlikely to provide adequate protection against the coronavirus. It will instead focus its COVID-19 research and production capabilities on two therapeutic drugs for the disease.

Merck had hinted at a conference last month that the efficacy rates of Moderna‘s mRNA vaccine and the one developed by collaboration partners Pfizer and BioNTech were better than it had expected, and set a high bar for its efforts. As it turned out, V590 and V591 produced immune responses that were inferior not only to those produced by other vaccines, but to those seen in patients who have recovered from COVID-19 infections.

Syringe and torn paper with "Coronavirus" written on it.

Image source: Getty Images.

Merck is the second-largest vaccine seller in the world, but had hesitated to develop one for COVID-19, falling months behind in the race. Eventually, it launched programs to develop single-dose vaccine candidates based on proven technology, one using the viral vector Merck uses in its approved Ebola vaccine, and one from a company it acquired last year in the hope of getting multiple shots on the COVID-19 goal. Instead, Merck will take a non-cash charge to its fourth-quarter earnings for the programs.

However, the pharma company still has high hopes for two COVID-19 treatment candidates. MK-7110 is an anti-inflammatory drug that appears to reduce the risk of death or respiratory failure in moderately to severely ill COVID-19 patients by as much as 50%. Phase 3 trial results for it are expected in the first quarter. Molnupiravir (MK-4482) is an oral antiviral being evaluated in trials that are expected to be complete in May. If successful, that drug could compete with Gilead‘s remdesivir, which faces some skepticism over its efficacy.

Let’s block ads! (Why?)



Source link

Continue Reading

Trending